A significant shift in Canadian drug policy has taken place, as the regulators allow the availability of psilocybin mushrooms for therapeutic applications. Until now, these substances were severely restricted, but a mounting body of evidence suggests they potentially offer benefits for emotional conditions like anxiety. The new policy represents a